media – Page 147 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Bessel launches accelerator program for medtech startups

BY JIM HAMMERAND Bessel and an Alabama tech hub today said they are launching Hatch Powered by Bessel, an accelerator program for medtech startups. Applications are now open for the 10-week program, which starts in Fairhope, Alabama, this summer. The accelerator “combines the passion of startup founders, the guidance of seasoned medical device experts, and the burgeoning startup ecosystem and investment in Alabama,” Bessel said in a news release. “… The program aims to equip medtech startups to create sustainable and scalable innovations—breakthroughs that scale—and to give founders the entrepreneurial resource ecosystem they need for long-term success.” Startups selected for the program will receive a travel stipend, access to events and workshops, and guidance on strategy, fundraising and execution from lifescience industry entrepreneurs who will act as mentors and advisors. The startups may be offered funding for equity by Hatch Fairhope after the cohort concludes with finale events in Fairhope, ...
- Source: drugdu
- 137
- April 7, 2024
Cambridge researchers begin new trial for oesophageal cancer screening

Researchers at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge have announced the launch of the BEST4 trial to evaluate a capsule sponge test to prevent oesophageal cancer. Funded by Cancer Research UK and the National Institute for Health and Research, the capsule sponge could see routine screening introduced into the NHS if successful. Responsible for around 9,200 new cases every year in the UK, oesophageal cancer occurs in the long, hollow tube that runs from the throat to the stomach, known as the oesophagus. The BEST4 trial, launched at Addenbrooke’s Hospital, is investigating whether the pill-on-a-thread test can be used to screen or monitor those most at risk of the disease. The ten-minute test is used for Barrett’s oesophagus, sometimes called a pre-cancerous condition, which is usually identified via an endoscopy and a biopsy at a hospital, following a GP referral. The process is time-consuming, unpleasant ...
- Source: drugdu
- 80
- April 7, 2024
Kanabo and City Dock Pharmacy team up

Kanabo Group has linked up with City Dock Pharmacy in London, to introduce a walk-in pain clinic offering specialised medicines, including medicinal cannabis. The partnership will cater for patients who are eligible for alternative therapies, as traditional treatments have not delivered improvements. The facility, which will be situated at City Dock Pharmacy in Wapping, will deliver both walk-in and appointment-related services, and becomes the UK’s first walk-in clinic for pain management. The clinic will represent an extension of Kanabo’s ‘Treat It’ online platform, allowing onsite pharmacists will also be able to guide patients through the medicinal cannabis treatment options. Meanwhile, the clinic will also support the unrolling of personalised plans for the growing number of chronic pain sufferers across the UK. At present, such individuals often face difficulties accessing medical treatments due to long waiting times and affordability. The latest development is part of Kanabo’s wider ambition to extend its ...
- Source: drugdu
- 83
- April 7, 2024
CellVoyant secures £7.6 million AI stem cell boost

CellVoyant – an AI biotechnology spin-out from the University of Bristol – has announced a £7.6 million funding round. Led by Octopus Ventures – with additional participation from Horizons Ventures, Air Street Capital and Verve Ventures – the funding represents the first stage in commercialising CellVoyant’s first of its kind AI and imaging platforms. Meanwhile, the company now aims to enable the rapid development of novel cell therapies. Stem cells unlock a wide range of treatment possibilities that have not historically been available to patients. Indeed, current treatments tend to act on the body’s existing cells, while stem cells have the potential to develop into different cell types in the body – replacing dysfunctional cells or regenerating damaged tissues and organs. CellVoyant’s platform combines advanced AI with live cell imaging to address pain points. The technology can extract spatial and temporal information in real-time from hundreds of millions of cells. ...
- Source: drugdu
- 108
- April 7, 2024
Aston University receives £10m for membrane institute

Aston University is on course to create the Aston Institute for Membrane Excellence (AIME) – a cross-disciplinary facility to develop novel biomimetic membranes – having received £10m from Research England. The institute will be led by Professor Roslyn Bill, from the School of Biosciences, along with Professor Paul Topham from the department of Chemical Engineering and Applied Chemistry. Both biological and synthetic membranes are significant across several many sectors. Indeed, the world’s top ten selling human medicines all target proteins in biological membranes, while synthetic polymer membranes are commonly used in the water purification industry. The AIME believes that the full potential of membranes will only be realised by an interdisciplinary group which spans biology, physics and chemistry and that can investigate membranes holistically. Professor Bill, a European Research Council (ERC) Advanced grantee leads Aston Membrane Proteins and Lipids (AMPL) research centre of excellence that studies the structure and function ...
- Source: drugdu
- 139
- April 7, 2024
Disco tunes into new cancer drug targets

EUR 20m to identify new targets and develop first in class drugs DISCO Pharmaceuticals – a company specialising in unlocking the surfaceome of cancer cells at scale – has raided EUR 20m to identify new targets and develop first in class drugs. The funding round was backed by a formidable investor syndicate, including Sofinnova Partners, Panakes Partners, M Ventures and AbbVie Ventures. The development of new treatment modalities in oncology is increasing, however, the lack of cell surface targets limits the application to some clinically effective targets. Also, the development of new biologics, such as bi-specific antibodies and antibody drug conjugates, is increasing and there are currently less than 30 molecular targets, which form the basis of all antibody-based therapies. Consequently, there is a significant need to identify novel cancer-selective targets and target pairs. DISCO’s surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. This ...
- Source: drugdu
- 113
- April 7, 2024
Poolbeg’s cytokine release syndrome drug shows potential

Data supports Poolbeg’s strategic expansion of POLB 001 Poolbeg – a company focused on innovative medicines – has announced promising in vivo results for POLB 001 in treating cancer immunotherapy-induced cytokine release syndrome (CRS). The drug showed efficacy in significantly reducing the condition in an animal model with CRS symptoms. The data further supports Poolbeg’s strategic expansion of the phase II-ready POLB 001 while the emerging results facilitate the expansion of patent applications for the therapy. As an oral therapy to prevent or treat CRS, POLB 001 has the potential to enable a broader use of cancer immunotherapies in an outpatient setting. Meanwhile, cancer immunotherapies are being developed through a considerable range of haematological malignancies, solid tumours and immune inflammatory diseases, which represents an even greater market opportunity. Due to the CRS risk – which can be life threatening – administration of cancer immunotherapies, such as bispecific antibodies, is currently ...
- Source: drugdu
- 104
- April 7, 2024
Baxter receives FDA clearance for delayed Novum IQ infusion pump

Dive Brief Baxter has received 510(k) clearance for its large volume infusion pump (LVP) Novum IQ, the company said Monday. The clearance follows three years of talks with the Food and Drug Administration, in which time a delay to the authorization drove Baxter to wipe $100 million in sales off its forecast in 2022. A Baxter spokesperson said in an email that the company will update 2024 guidance on its upcoming first-quarter earnings call and expects Novum IQ to be a meaningful contributor to future growth. Evercore ISI analysts said the success of Baxter’s Spectrum pumps and the return of BD’s Alaris to the market means the $100 million annual sales assumption no longer applies. Even so, Evercore and Stifel analysts called the clearance positive for Baxter in notes to investors. Dive Insight The FDA identified an issue with Baxter’s filing for clearance of the LVP version of Novum IQ ...
- Source: drugdu
- 142
- April 5, 2024
Abbott nets FDA approval for Triclip

Dive Brief Abbott said Tuesday it received the Food and Drug Administration’s approval to market a transcatheter device for repairing the tricuspid valve in patients who are unable to withstand open-heart surgery. The go-ahead from the FDA paves the way for Abbott’s Triclip repair system to compete in the U.S. against Edwards Lifesciences’ recently approved transcatheter tricuspid valve replacement device, Evoque. Triclip uses the same clip-based technology to treat tricuspid regurgitation as Abbott’s Mitraclip for mitral valve regurgitation, a device the company has credited with driving double-digit growth in its structural heart business. Dive Insight Valve regurgitation, or leaking, occurs when the heart valve does not close correctly as it opens and shuts to circulate blood. The tricuspid valve controls blood flow from the right atrium to the right ventricle. When the valve isn’t closing properly, blood can flow backward in the heart, forcing it to work harder. Most common ...
- Source: drugdu
- 138
- April 5, 2024
Alebund receives ODD for investigational drug AP303

Alebund Pharmaceuticals has received the US Food and Drug Administration’s (FDA) orphan drug designation (ODD) for its investigational drug AP303. This designation is intended for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder that causes the growth of numerous cysts in the kidneys. AP303 is an internally developed drug candidate that has shown promise in improving renal survival in an ADPKD mice model. The drug has successfully completed a first-in-human study in healthy subjects in Australia and is poised to enter Phase II trials. ADPKD has a prevalence of between one in 400 and one in 1,000 live births and is a significant cause of end-stage kidney disease (ESKD), which often necessitates renal replacement therapy. Alebund co-founder, chairman, and CEO Dr Gavin Xia said: “We are very excited that AP303 has been granted orphan drug designation by the FDA. “It is an important milestone for Alebund ...
- Source: drugdu
- 130
- April 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.